CClinicalTrials.gg
WithdrawnNCT01098864Updated Mar 4, 2015

Transcranial Magnetic Stimulation of the Prefrontal Cortex: Effects on Risky Decision Making and Temporal Discounting.

An interventional study of transcranial magnetic stimulation in Decision Making, sponsored by University of Arkansas. Withdrawn. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-04.

Sponsored by University of Arkansas · Not applicable and Interventional

Why this study was withdrawn
Study was withdrawn prior to the first subject being enrolled due to the Co-Investigator leaving the university
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main objective of this study is to examine the effects of magnetic stimulation on the prefrontal cortex. We plan to use low frequency, repeated transcranial magnetic stimulation (1 Hz rTMS) to temporarily inhibit activity in the prefrontal cortex and measure the resulting effect on two decision-making tasks. The prefrontal cortex is thought to mediate or control cognitive functions like decision-making, planning, memory, and inhibit impulsive behavior.Previous research has indicated that rTMS over the right dorsal lateral prefrontal cortex will lead to preferences for riskier alternatives. Our hypothesis is that rTMS over the right DLPFC will lead to greater preference for the riskier alternative and greater temporal discounting.

02

Conditions studied

  • Decision Making

Keywords

  • Behavior
  • Impulsivity
  • Transcranial Magnetic Stimulation
03

In context

Lead sponsor

University of Arkansas is the lead sponsor of 391 studies on the registry; 39 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 34 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy participants willing to give informed consent to participate
  • complete the Transcranial magnetic stimulation Adult Safety Screen
  • have a MRI scan
  • wear ear plugs during rTMS
  • receive rTMS over the designated course of days
  • complete cognitive assessments and decision making tasks.
  • return for post-testing on all tasks after completing all rTMS sessions

Exclusion criteria

Exclusion Criteria:

  • Diagnosed neurological and/or psychiatric disorders requiring hospitalization or medication
  • pregnancy or the possibility of pregnancy at the time of consent
  • a history of tinnitus
  • metal implants in head or neck or a pacemaker
  • poorly-controlled migraines
  • a history of head injury, stroke, previous brain neurosurgery, or loss of consciousness due to head injury lasting greater than 10 minutes
  • a personal or family history of epilepsy or seizures
05

Study design

Phase
Not applicable
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Interventions

  • Devicetranscranial magnetic stimulation

    low frequency (1 Hz) repeated transcranial magnetic stimulation will be delivered to the dorsal lateral prefrontal cortex (DLPFC) area for a period of 15 minutes to test for effect on executive function (e.g., decision choice and subjective value). Four sessions will be conducted per subject; 2 active stimulations,(1 left DLPFC, 1 right DLPFC) and 2 sham stimulations (1 left DLPFC, 1 right DLPFC) with a minimum of 48 hours between every stimulation. Pre and post stimulations measures of cognitive and executive function will be collected and analyzed for significant differences.

    Also known as: Magstim Super Rapid 2 Stimulator w/ 70mm figure eight stimulating coil

06

What researchers measure

Primary outcomes

  1. The k metric of a hyperbolic function for delayed discounting

    Time frame: 12-18 weeks

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 4, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01098864
Lead sponsor
University of Arkansas
First posted
Apr 5, 2010
Start date
May 2011
Primary completion
Jan 2014 (estimated)
Completion
Jan 2014 (estimated)
Last update
Mar 4, 2015

Study contacts

Mark S Mennemeier, PhD
principal investigator · Universtiy of Arkansas for Medical Sciences

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion